Holen Sie sich die Stockscreener-App
0.7143
4.66%
-0.0353
Schlusskurs vom Vortag:
$0.7496
Offen:
$0.72
24-Stunden-Volumen:
670.91K
Relative Volume:
0.61
Marktkapitalisierung:
$76.40M
Einnahmen:
$33.03M
Nettoeinkommen (Verlust:
$-44.63M
KGV:
-1.7036
EPS:
-0.4193
Netto-Cashflow:
$-36.18M
1W Leistung:
+5.69%
1M Leistung:
-8.65%
6M Leistung:
-56.68%
1J Leistung:
-70.83%
1-Tages-Spanne:
$0.7149
$0.7604
1-Wochen-Bereich:
$0.66
$0.7619
52-Wochen-Spanne:
$0.6434
$2.955
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
0.7149 | 80.10M | 33.03M | -44.63M | -36.18M | -0.4193 |
ABT
Abbott Laboratories
|
102.08 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.93 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.20 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.48 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.99 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MXCT PE Ratio & Valuation, Is MXCT Overvalued - Intellectia AI
MXCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN
Big Money Moves: Is MaxCyte Inc stock risky to hold now2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs - Stock Titan
New MaxCyte CFO gets 562,500-share inducement award under Nasdaq rule - Stock Titan
RSI Check: Is now the right time to enter MaxCyte IncTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Risk On: Will MaxCyte Inc outperform small cap indexes2026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
MaxCyte sees Q4 core revenue between $6.6M and $6.7M - MSN
MaxCyte Appoints Parmeet Ahuja as New Chief Financial Officer to Drive Strategic Growth - Minichart
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook - MSN
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates - MSN
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside - The Globe and Mail
MaxCyte Appoints New Chief Financial Officer Ahuja - TipRanks
MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky - TradingView
New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent - Stock Titan
Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT) - Stock Titan
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development - Minichart
MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42) - TradingView
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan
MXCT: Craig-Hallum Maintains Buy Rating but Lowers Price Target - GuruFocus
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds By Investing.com - Investing.com Australia
Craig Hallum Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - MarketBeat
Stifel cuts MaxCyte stock price target on 2026 revenue guidance - Investing.com
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds - Investing.com
Stifel cuts MaxCyte stock price target on 2026 revenue guidance By Investing.com - Investing.com Australia
MaxCyte 2025 Financial Results Review - AlphaStreet
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript - MSN
MaxCyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript - insidermonkey.com
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 - Minichart
MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... By GuruFocus - Investing.com Canada
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
MaxCyte, Inc. (MXCT) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MaxCyte Q4 Earnings Call Highlights - MarketBeat
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts - Investing.com
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts By Investing.com - Investing.com Australia
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook - TipRanks
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hemrajani Rekha | Director |
Jun 25 '25 |
Sale |
2.09 |
10,684 |
22,378 |
39,893 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
0.25%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):